Both O
Ala O
67 O
and O
Thr O
67 O
Ag O
RP O
colocalised O
with O
the O
Golgi O
apparatus O
, O
but O
not O
with O
the O
ER O
or O
lysosomes O
when O
expressed O
in O
Att O
20 O
D O
16 O
V O
cells O
. O

A O
similar O
peptide O
with O
glutamic B
acid I
replacing I
Ser I
( I
748 I
) I
was O
preferentially O
phosphorylated O
by O
PKCepsilon O
, O
suggesting O
that O
PKD O
containing O
phosphate O
at O
Ser O
( O
748 O
) O
is O
rapidly O
targeted O
by O
this O
isoform O
at O
Ser O
( O
744 O
) O
. O

The O
high O
constitutive O
activity O
of O
the O
pleckstrin O
homology O
( O
PH O
) O
domain O
deletion O
mutant O
PKD O
- O
delta O
PH O
was O
not O
abrogated O
by O
mutation B
of I
Ser I
( I
744 I
) I
and O
Ser B
( I
748 I
) I
to I
alanines I
, O
suggesting O
that O
one O
function O
of O
activation O
loop O
phosphorylation O
in O
the O
PKD O
activation O
mechanism O
is O
to O
relieve O
autoinhibition O
by O
the O
PH O
domain O
. O

These O
studies O
provide O
evidence O
of O
a O
direct O
PKCepsilon O
- O
PKD O
phosphorylation O
cascade O
and O
provide O
additional O
insight O
into O
the O
activation O
mechanism O
. O

In O
the O
human O
protein O
, O
sequence B
substitution I
of I
tyrosine I
by I
histidine I
at I
this I
critical I
position I
generated O
a O
mutant O
that O
displays O
almost O
identical O
proton O
sensitivity O
compared O
with O
mouse O
TRESK O
. O

However O
, O
in O
current O
- O
clamp O
recordings O
we O
observed O
significant O
changes O
in O
action O
potential O
duration O
and O
amplitude O
of O
after O
- O
hyperpolarization O
. O

FLT O
3 O
- O
ITDs O
confer O
factor O
- O
independent O
growth O
to O
hematopoietic O
cells O
and O
induce O
a O
myeloproliferative O
syndrome O
in O
murine O
bone O
marrow O
transplant O
models O
. O

Tyrosine B
to I
phenylalanine I
substitution I
of I
residues I
589 I
and I
591 I
in O
the O
context O
of O
the O
FLT O
3 O
- O
ITD O
did O
not O
affect O
tyrosine O
kinase O
activity O
, O
but O
abrogated O
STAT O
5 O
activation O
. O

SADB O
exerted O
this O
action O
through O
phosphorylation O
of O
gamma O
- O
tubulin O
on O
Ser O
131 O
, O
as O
expression O
of O
a O
phosphomimetic O
Ser B
131 I
- I
to I
- I
Asp I
gamma O
- O
tubulin O
mutant O
alone O
increased O
centrosome O
numbers O
, O
whereas O
non O
- O
phosphorylatable O
Ala O
131 O
- O
gamma O
- O
tubulin O
impaired O
centrosome O
duplication O
. O

Deletion B
of I
the I
C I
6 I
motif I
of O
mouse O
Axin O
in O
vivo O
reduced O
the O
steady O
- O
state O
protein O
level O
, O
which O
caused O
embryonic O
lethality O
. O

Although O
C O
6 O
deletion O
also O
caused O
increased O
association O
of O
Axin O
with O
Dvl O
- O
1 O
, O
this O
interaction O
was O
not O
altered O
by O
mutating B
the I
lysine I
residues I
in I
C I
6 I
, O
nor O
could O
heterologous O
SUMOylation O
moti O
fs O
replace O
the O
C O
6 O
motif O
in O
this O
assay O
. O

Therefore O
, O
some O
other O
specific O
property O
of O
the O
C O
6 O
motif O
seems O
to O
reduce O
the O
interaction O
of O
Axin O
with O
Dvl O
- O
1 O
. O

On O
a O
per O
molecule O
basis O
, O
Mprocida O
has O
a O
mildly O
reduced O
function O
as O
an O
inhibitor O
, O
with O
an O
association O
rate O
constant O
for O
human O
neutrophil O
elastase O
of O
7 O
. O
0 O
+ O
/ O
- O
0 O
. O
1 O
x O
10 O
( O
6 O
) O
M O
- O
1 O
s O
- O
1 O
( O
normal O
M O
1 O
( O
Val O
213 O
) O
9 O
. O
3 O
+ O
/ O
- O
0 O
. O
8 O
x O
10 O
( O
6 O
) O
, O
p O
less O
than O
0 O
. O
01 O
) O
. O

Sequencing O
of O
all O
the O
exons O
, O
exon O
- O
intron O
junctions O
, O
and O
the O
major O
promoter O
region O
demonstrated O
Mprocida O
to O
be O
identical O
to O
the O
M B
1 I
( I
Val I
213 I
) I
gene I
except I
for I
a I
single I
base I
substitution I
in I
exon I
II I
coding I
for I
amino I
acid I
41 I
of O
the O
mature O
protein O
( B
M I
1 I
( I
Val I
213 I
) I
Leu I
41 I
CTG I
- I
- I
- I
- I
Mprocida I
Pro I
41 I
CCG I
) I
. O

Evaluation O
of O
the O
crystallographic O
structure O
of O
alpha O
1 O
AT O
suggests O
the O
Leu B
41 I
to I
Pro I
41 I
mutation O
may O
disrupt O
alpha O
- O
helix O
A O
in O
the O
region O
of O
Pro O
21 O
- O
Ser O
45 O
, O
suggesting O
the O
possibility O
that O
the O
alpha O
1 O
AT O
Mprocida O
molecule O
is O
unstable O
and O
degraded O
intracellularly O
prior O
to O
secretion O
. O

Recently O
, O
we O
demonstrated O
that O
circadian O
activation O
of O
the O
heterodimeric O
transcription O
factor O
is O
accompanied O
by O
ubiquitin O
- O
dependent O
proteolysis O
of O
BMAL O
1 O
. O

Interestingly O
, O
mutation B
of I
the I
sumoylation I
site I
( I
Lys I
( I
259 I
) I
) I
of O
BMAL O
1 O
markedly O
inhibited O
both O
its O
ubiquitination O
and O
its O
proteasome O
- O
mediated O
proteolysis O
, O
and O
these O
effects O
were O
reversed O
by O
covalent O
attachment O
of O
SUMO O
3 O
to O
the O
C O
terminus O
of O
the O
mutant O
BMAL O
1 O
. O

Combining O
these O
results O
with O
previously O
determined O
sequences O
for O
A O
25 O
, O
A O
26 O
and O
A O
66 O
enables O
molecular O
comparison O
of O
all O
the O
serologically O
defined O
A O
10 O
antigens O
. O

The O
rare O
Oriental O
variant O
of O
A O
26 O
( O
A O
26 O
v O
* O
) O
is O
encoded O
by O
an O
allele O
( O
A O
* O
2602 O
) O
that O
differs O
from O
A O
* O
2601 O
by O
a O
unique O
nucleotide O
substitution O
which O
changes O
aspartate B
to I
asparagine I
at I
position I
116 I
in O
the O
floor O
of O
the O
peptide O
binding O
groove O
. O

No O
genetic O
polymorphism O
has O
previously O
been O
identified O
in O
the O
beta O
( O
1 O
) O
- O
adrenergic O
receptor O
gene O
. O

A O
missense B
mutation I
was I
identified I
at I
nucleotide I
position I
145 I
in O
the O
beta O
( O
1 O
) O
- O
adrenergic O
receptor O
gene O
, O
which O
predicted O
an O
amino B
acid I
substitution I
at I
position I
49 I
( O
Ser O
49 O
Gly O
) O
. O

The O
gp O
D O
c O
DNAs O
isolated O
by O
reverse O
transcription O
/ O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
from O
Fy O
( O
a O
+ O
b O
- O
) O
and O
Fy O
( O
a O
- O
b O
+ O
) O
donors O
differed O
by O
only O
one O
base O
substitution O
( O
G O
131 O
A O
) O
changing O
Gly B
to I
Asp I
at I
position I
44 I
of O
the O
gp O
D O
protein O
. O

Zaug O
sequence O
data O
analysis O
showed O
the O
presence O
of O
the O
common O
PI O
* O
Z O
allele O
- O
specific O
mutation O
( O
M B
1 I
Glu I
342 I
GAG I
to I
Z I
Lys I
342 I
AAG I
) O
surprisingly O
occurring O
in O
an O
M O
2 O
ancestral O
gene O
. O

No O
further O
mutations O
were O
found O
in O
the O
PI O
Zaug O
gene O
. O

Aside O
from O
mutation B
of I
a I
catalytic I
tetrad I
residue I
, O
proline B
residues I
at I
positions I
670 I
and I
675 I
in O
h O
AGO O
1 O
introduce O
a O
kink O
in O
the O
c O
S O
7 O
loop O
, O
forming O
a O
convex O
surface O
within O
the O
h O
AGO O
1 O
nucleic O
- O
acid O
- O
binding O
channel O
near O
the O
inactive O
catalytic O
site O
. O

Direct O
sequencing O
of O
DNA O
from O
a O
family O
with O
autopsy O
- O
proven O
Alzheimer O
' O
s O
disease O
revealed O
a O
single B
amino I
acid I
substitution I
( I
Phe I
for I
Val I
) I
in I
the I
transmembrane I
domain I
of O
the O
amyloid O
precursor O
protein O
. O

Phosphorylation O
of O
this O
site O
enhanced O
the O
DNA O
binding O
and O
transcriptional O
activity O
of O
MEF O
2 O
C O
by O
increasing O
its O
DNA O
binding O
activity O
5 O
- O
fold O
. O

Mutagenesis B
of I
this I
serine I
to I
an I
aspartic I
acid I
resulted O
in O
an O
increase O
in O
DNA O
binding O
and O
transcriptional O
activity O
of O
MEF O
2 O
C O
comparable O
to O
that O
observed O
when O
this O
site O
was O
phosphorylated O
, O
suggesting O
that O
phosphorylation O
augments O
DNA O
binding O
activity O
by O
introducing O
negative O
charge O
. O

All O
50 O
exons O
of O
the O
ABCR O
gene O
were O
analyzed O
by O
single O
- O
stranded O
confirmation O
polymorphism O
analysis O
, O
followed O
by O
direct O
sequencing O
of O
observed O
variants O
, O
to O
identify O
mutations O
in O
the O
ABCR O
gene O
. O

A O
previously O
described O
G B
- I
to I
- I
C I
transversion I
of I
nucleotide I
2588 I
, O
predicting O
a O
Gly O
863 O
Ala O
amino O
acid O
substitution O
, O
and O
a O
novel O
G B
- I
to I
- I
A I
transition I
of I
nucleotide I
161 I
, O
resulting O
in O
a O
Cys O
54 O
Tyr O
substitution O
, O
were O
identified O
. O

We O
demonstrate O
that O
ABC O
50 O
is O
a O
phosphoprotein O
and O
is O
phosphorylated O
at O
two O
sites O
by O
CK O
2 O
. O

Expression O
of O
a O
mutant O
of O
ABC O
50 O
in O
which O
both B
sites I
are I
mutated I
to I
alanine I
markedly O
decreased O
the O
association O
of O
e O
IF O
2 O
with O
80 O
S O
ribosomal O
and O
polysomal O
fractions O
. O

Substitution B
of I
aspartate I
79 I
with I
asparagine I
produced O
a O
mutant O
receptor O
that O
displays O
the O
expected O
affinity O
and O
stereoselectivity O
for O
antagonists O
but O
a O
40 O
- O
, O
140 O
- O
, O
and O
240 O
- O
fold O
reduction O
in O
its O
affinity O
for O
isoproterenol O
, O
epinephrine O
, O
and O
norepinephrine O
, O
respectively O
. O

These O
observations O
demonstrate O
that O
substitution B
of I
aspartate I
with I
asparagine I
at I
residue I
79 I
in O
the O
human O
beta O
- O
adrenergic O
receptor O
differentially O
affects O
the O
binding O
of O
catecholamines O
and O
produces O
a O
functional O
uncoupling O
of O
receptors O
and O
stimulatory O
guanine O
nucleotide O
regulatory O
proteins O
( O
Gs O
) O
. O

Using O
intronic O
primers O
, O
we O
were O
able O
to O
detect O
the O
gene O
alterations O
on O
the O
genomic O
DNA O
of O
the O
patients O
. O

The O
four B
nucleotides I
deletion I
located I
at I
the I
junction I
of I
exon I
/ I
intron I
16 I
( O
5 O
' O
- O
TTGGTCGgtgagt O
- O
3 O
' O
) O
is O
the O
first O
GPI O
mutation O
affecting O
a O
splice O
site O
. O

Four O
genes O
were O
screened O
for O
mutations O
and O
a O
homozygous O
substitution O
was O
identified O
in O
ACAD O
9 O
( O
c O
. O
1594 O
C O
> O
T O
) O
, O
changing B
the I
highly I
conserved I
arginine I
- I
532 I
into I
tryptophan I
. O

Wild O
- O
type O
, O
but O
not O
mutant O
, O
ACAD O
9 O
restored O
complex O
I O
activity O
. O

An O
unrelated O
patient O
with O
the O
same O
phenotype O
was O
compound O
heterozygous O
for O
c O
. O
380 O
G O
> O
A O
and O
c O
. O
1405 O
C O
> O
T O
, O
changing O
arginine B
- I
127 I
into I
glutamine I
and O
arginine B
- I
469 I
into I
tryptophan I
, O
respectively O
. O

Using O
a O
positional O
candidate O
- O
gene O
approach O
, O
we O
determined O
the O
ttw O
phenotype O
is O
caused O
by O
a O
nonsense O
mutation O
( O
glycine B
568 I
to I
stop I
) O
in O
the O
Npps O
gene O
which O
encodes O
nucleotide O
pyrophosphatase O
. O

Reverse O
transcriptase O
PCR O
( O
RT O
- O
PCR O
) O
analysis O
was O
performed O
using O
direct O
sequencing O
of O
the O
obtained O
fragments O
. O

A O
homozygous B
G I
> I
A I
substitution I
( I
c I
. I
666 I
G I
> I
A I
) I
at I
the I
last I
nucleotide I
of I
exon I
6 I
in O
the O
ALDH O
1 O
A O
3 O
gene O
was O
identified O
in O
the O
first O
family O
. O

Further O
c O
DNA O
sequencing O
of O
ALDH O
1 O
A O
3 O
showed O
that O
the O
c O
. O
666 O
G O
> O
A O
mutation O
caused O
skipping O
of O
exon O
6 O
, O
which O
predicted O
in B
- I
frame I
loss I
of I
43 I
amino I
acids I
( O
p O
. O
Trp O
180 O
_ O
Glu O
222 O
del O
) O
. O

A O
novel B
missense I
c I
. I
1398 I
C I
> I
A I
mutation I
in I
exon I
12 I
of O
ALDH O
1 O
A O
3 O
that O
causes O
the O
substitution B
of I
a I
conserved I
asparagine I
by I
lysine I
at I
amino I
acid I
position I
466 I
( O
p O
. O
Asn O
466 O
Lys O
) O
was O
observed O
in O
the O
second O
family O
. O

Mutations O
at O
the O
W O
locus O
affect O
various O
aspects O
of O
hematopoiesis O
, O
the O
proliferation O
and O
migration O
of O
primordial O
germ O
cells O
and O
melanoblasts O
during O
development O
. O

We O
show O
that O
W O
37 O
, O
Wv O
and O
W O
41 O
are O
the O
result O
of O
missense O
mutations O
in O
the O
kinase O
domain O
of O
the O
c O
- O
kit O
coding O
sequence O
( O
W O
37 O
E O
- O
- O
- O
- O
K O
at O
position O
582 O
; O
Wv B
T I
- I
- I
- I
- I
M I
position I
660 I
and O
W O
41 O
V O
- O
- O
- O
- O
M O
position O
831 O
) O
, O
which O
affect O
the O
c O
- O
kit O
associated O
tyrosine O
kinase O
to O
varying O
degrees O
. O

The O
W O
mutation O
is O
the O
result O
of O
a O
78 B
amino I
acid I
deletion I
which I
includes I
the I
transmembrane I
domain I
of O
the O
c O
- O
kit O
protein O
. O

We O
investigated O
the O
molecular O
mechanism O
by O
which O
a O
single B
phenylalanine I
deletion I
in O
SUR O
1 O
( O
Delta O
F O
1388 O
) O
causes O
PHHI O
. O

To O
ask O
whether O
Delta O
F O
1388 O
SUR O
1 O
forms O
functional O
channels O
with O
Kir O
6 O
. O
2 O
, O
we O
inactivated O
the O
RKR O
signal O
in O
Delta B
F I
1388 I
SUR I
1 I
by I
mutation I
to I
AAA I
( I
Delta I
F I
1388 I
SUR I
1 I
( I
AAA I
) I
) I
. O

We O
found O
that O
coexpression O
of O
Delta O
F O
1388 O
SUR O
1 O
( O
AAA O
) O
with O
Kir O
6 O
. O
2 O
led O
to O
partial O
surface O
expression O
of O
the O
mutant O
channel O
. O

Inhibition O
of O
both O
CK O
2 O
α O
and O
DBC O
1 O
decreased O
proliferation O
and O
invasive O
activity O
of O
cancer O
cells O
. O

A O
mutation B
at I
the I
phosphorylation I
site I
of O
DBC O
1 O
also O
downregulated O
the O
signals O
related O
with O
the O
epithelial O
- O
mesenchymal O
transition O
. O

Clinical O
characteristics O
in O
a O
kindred O
with O
early O
- O
onset O
Alzheimer O
' O
s O
disease O
and O
their O
linkage O
to O
a O
G B
- I
- I
> I
T I
change I
at I
position I
2149 I
of O
the O
amyloid O
precursor O
protein O
gene O
. O

Patients O
from O
five O
generations O
of O
a O
family O
developed O
presenile O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
early O
in O
the O
fifth O
decade O
. O

Direct O
DNA O
sequencing O
revealed O
a O
G B
- I
- I
> I
T I
change I
at I
position I
2149 I
of O
the O
amyloid O
precursor O
protein O
( O
APP O
) O
gene O
that O
resulted O
in O
the O
substitution B
of I
phenylalanine I
for I
valine I
in I
the I
transmembrane I
domain I
of O
the O
mature O
protein O
. O

RESULTS O
: O
Five O
missense O
mutations O
producing O
amino O
acid O
substitutions O
were O
detected O
in O
the O
four O
colon O
cancer O
cases O
( O
13 O
. O
3 O
% O
; O
four O
of O
30 O
colorectal O
cancers O
) O
: O
( B
15 I
) I
glycine I
( I
GGT I
) I
to I
alanine I
( I
GCT I
) I
and O
( B
499 I
) I
leucine I
( I
TTA I
) I
to I
isoleucine I
( I
ATA I
) I
in O
the O
same O
case O
, O
and O
( B
498 I
) I
valine I
( I
GTG I
) I
to I
glutamic I
acid I
( I
GAG I
) I
, O
( B
500 I
) I
valine I
( I
GTA I
) I
to I
glycine I
( I
GGA I
) I
, O
and O
( B
365 I
) I
serine I
( I
TCT I
) I
to I
proline I
( I
CCT I
) I
. O

CONCLUSION O
: O
Our O
results O
suggest O
that O
the O
PPP O
2 O
R O
1 O
B O
gene O
is O
one O
of O
the O
true O
targets O
at O
11 O
q O
23 O
, O
and O
its O
inactivation O
is O
involved O
in O
the O
development O
of O
all O
types O
of O
colorectal O
cancers O
. O

Mutations O
in O
AGRIN O
( O
AGRN O
) O
and O
other O
genes O
in O
the O
AGRIN O
signaling O
pathway O
cause O
CMS O
, O
and O
gene O
targeting O
studies O
in O
mice O
confirm O
the O
importance O
of O
this O
pathway O
for O
NMJ O
formation O
. O

The O
mutation O
changes O
phenylalanine B
1061 I
to I
serine I
in O
the O
SEA O
domain O
of O
AGRIN O
, O
a O
poorly O
characterized O
motif O
shared O
by O
other O
extracellular O
proteoglycans O
. O

Mutational O
experiments O
were O
performed O
by O
introducing B
a I
substitution I
, I
GG I
to I
AT I
, I
into I
the I
INSM I
1 I
core I
binding O
site O
of O
the O
rat O
insulin O
I O
/ O
II O
promoters O
. O

These O
data O
strongly O
support O
the O
view O
that O
INSM O
1 O
is O
a O
new O
zinc O
- O
finger O
transcription O
factor O
that O
modulates O
insulin O
gene O
transcription O
during O
early O
pancreas O
development O
. O

We O
found O
that O
two O
common O
alleles O
, O
C O
8 O
A O
* O
A O
and O
C O
8 O
A O
* O
B O
, O
are O
characterized O
by O
the O
substitution B
of I
a I
single I
amino I
acid I
( I
Gln I
to I
Lys I
) I
, I
which I
is I
caused I
by I
a I
point I
mutation I
of I
a I
single I
nucleotide I
( I
C I
to I
A I
) I
in I
exon I
3 I
at I
position I
187 I
of O
the O
mature O
C O
8 O
alpha O
c O
DNA O
sequence O
. O

Genomic O
samples O
from O
46 O
unrelated O
healthy O
subjects O
were O
investigated O
by O
single O
- O
strand O
conformation O
analysis O
( O
SSCA O
) O
to O
screen O
for O
genetic O
variation O
in O
the O
human O
serotonin O
1 O
D O
beta O
( O
5 O
- O
HT O
1 O
D O
beta O
) O
receptor O
gene O
. O

Four O
nucleotide O
sequence O
variants O
were O
found O
: O
a O
coding O
mutation B
in I
nucleotide I
position I
371 I
which O
leads O
to O
an O
amino O
acid O
exchange O
( O
Phe B
- I
- I
> I
Cys I
) I
in I
position I
124 I
of O
the O
receptor O
protein O
and O
three O
mutations O
in O
the O
5 O
' O
flanking O
region O
. O

Affected O
infants O
have O
markedly O
impaired O
barrier O
function O
and O
are O
more O
susceptible O
to O
infection O
. O

A O
combination O
of O
oligonucleotide O
arrays O
, O
multiplex O
PCR O
analysis O
and O
single O
- O
nucleotide O
polymorphism O
genotyping O
revealed O
a O
heterozygous B
intragenic I
deletion I
in I
exon I
8 I
. O

Mutation O
of O
the O
P B
4 I
Arg I
to I
Gly I
completely O
prevented O
this O
conversion O
. O

pro O
7 O
B O
2 O
processing O
in O
At O
T O
- O
20 O
was O
completely O
abolished O
when O
protein O
transport O
into O
Golgi O
compartments O
was O
blocked O
by O
cell O
incubation O
at O
either O
15 O
or O
37 O
degrees O
C O
in O
the O
presence O
of O
monensin O
or O
brefeldin O
A O
. O

Most O
( O
approximately O
80 O
% O
) O
cases O
are O
homozygous O
for O
a O
single O
mutation O
: O
A B
to I
G I
replacement I
at I
nucleotide I
985 I
( I
A I
985 I
G I
) I
. O

Full O
- O
length O
c O
DNA O
and O
MCAD O
exon O
7 O
and O
11 O
genomic O
clones O
were O
prepared O
for O
sequence O
analysis O
. O

Four O
compound O
heterozygote O
individuals O
from O
two O
unrelated O
families O
with O
A O
985 O
G O
on O
one O
allele O
and O
a O
novel O
G B
to I
A I
mutation I
at I
nucleotide I
583 I
( O
G O
583 O
A O
) O
as O
the O
second O
mutant O
allele O
presented O
with O
MCAD O
deficiency O
in O
the O
first O
week O
of O
life O
. O

Molecular O
characterization O
of O
medium O
- O
chain O
acyl O
- O
Co O
A O
dehydrogenase O
( O
MCAD O
) O
deficiency O
: O
identification O
of O
a O
lys B
329 I
to I
glu I
mutation I
in O
the O
MCAD O
gene O
, O
and O
expression O
of O
inactive O
mutant O
enzyme O
protein O
in O
E O
. O
coli O
. O

All O
clones O
sequenced O
from O
the O
patient O
exhibited O
a O
single B
base I
substitution I
from I
adenine I
( I
A I
) I
to I
guanine I
( I
G I
) I
at I
position I
985 I
in O
the O
MCAD O
c O
DNA O
as O
the O
only O
consistent O
base O
- O
variation O
compared O
with O
control O
c O
DNA O
. O

Allelic O
homozygosity O
in O
the O
patient O
and O
heterozygosity O
for O
the O
mutation O
in O
the O
parents O
were O
established O
by O
a O
modified O
PCR O
reaction O
, O
introducing O
a O
cleavage O
site O
for O
the O
restriction O
endonuclease O
Nco O
I O
into O
amplified O
genomic O
DNA O
containing O
G O
985 O
. O

All O
the O
experiments O
are O
consistent O
with O
the O
contention O
that O
the O
G B
985 I
mutation I
, O
resulting B
in I
a I
lysine I
to I
glutamate I
shift I
at I
position I
329 I
in O
the O
MCAD O
polypeptide O
chain O
, O
is O
the O
genetic O
cause O
of O
MCAD O
deficiency O
in O
this O
family O
. O

The O
two O
polymorphic O
GPT O
isozymes O
are O
the O
results O
of O
a O
nucleotide B
substitution I
in I
codon I
14 I
, I
coding I
for I
a I
histidine I
in I
GPT I
- I
1 I
and I
an I
asparagine I
in I
GPT I
- I
2 I
, O
which O
causes O
a O
gain O
or O
loss O
of O
an O
Nla O
III O
restriction O
site O
. O

In O
addition O
, O
this O
will O
be O
a O
useful O
system O
for O
characterizing O
the O
telomeric O
region O
of O
8 O
q O
. O

This O
variant O
ACT O
was O
a O
point O
mutation O
of O
exon B
V I
of I
ACT I
, I
with I
the I
substitution I
of I
Met I
by I
Val I
. O

Amyloid O
fibrils O
were O
isolated O
from O
the O
brain O
tissue O
of O
two O
individuals O
who O
died O
with O
familial O
Alzheimer O
' O
s O
disease O
, O
one B
with I
the I
phenylalanine I
717 I
mutation I
in O
amyloid O
precursor O
protein O
( O
APP O
) O
and O
one B
with I
the I
isoleucine I
717 I
APP I
mutation I
. O

Two O
common O
mutations O
were O
identified O
: O
( O
I O
) O
a O
novel O
in B
- I
frame I
deletion I
of I
three I
nucleotides I
( I
nt I
) I
in I
exon I
34 I
, O
resulting B
in I
deletion I
of I
the I
codon I
for I
F I
1388 I
( I
delta I
F I
1388 I
) I
and O
( O
II O
) O
a O
previously O
described O
g B
- I
- I
> I
a I
transition I
at I
position I
- I
9 I
of I
the I
3 I
' I
splice I
site I
of I
intron I
32 I
( I
designated I
3992 I
- I
9 I
g I
- I
- I
> I
a I
) I
. O

Extended O
haplotype O
analyses O
indicated O
that O
the O
delta O
F O
1388 O
mutation O
was O
associated O
with O
a O
single O
specific O
haplotype O
whereas O
the O
3992 B
- I
9 I
g I
- I
- I
> I
a I
mutation I
was O
primarily O
associated O
with O
a O
single O
haplotype O
but O
also O
occurred O
in O
the O
context O
of O
several O
other O
different O
haplotypes O
. O

Sequence O
analysis O
of O
the O
proband O
' O
s O
ferrochelatase O
c O
DNA O
revealed O
a O
T B
to I
C I
point I
mutation I
at I
nucleotide I
557 I
. O

This O
mutation O
resulted O
in O
the O
replacement B
of I
Ile I
by I
Thr I
at I
amino I
acid I
position I
186 I
, O
a O
novel O
mutation O
in O
erythropoietic O
protoporphyria O
. O

The O
5 O
- O
hydroxytryptamine O
2 O
C O
( O
5 O
- O
HT O
( O
2 O
C O
) O
) O
receptor O
has O
a O
single B
nucleotide I
polymorphism I
( I
SNP I
) I
site I
at I
amino I
acid I
position I
23 I
in I
its I
N I
- I
terminal I
tail I
. O

Modifications O
included O
addition O
of O
the O
influenza O
virus O
hemagglutinin O
signal O
peptide O
, O
addition O
of O
a O
FLAG O
epitope O
, O
truncation B
of I
the I
N I
- I
terminal I
tail I
, O
and O
combinations O
of O
these O
changes O
. O

The O
results O
suggest O
the O
following O
conclusions O
. O

A O
duplication B
of I
the I
nine I
most I
3 I
' I
located I
nucleotides I
of I
exon I
49 I
and I
the I
first I
nucleotide I
of I
intron I
49 I
was O
identified O
in O
the O
COL O
4 O
A O
5 O
gene O
of O
one O
patient O
. O

Two O
patients O
displayed O
single O
base O
substitutions O
leading O
to O
, O
respectively O
, O
a O
proline B
to I
threonine I
and I
an I
arginine I
to I
glutamine I
substitution I
in I
the I
C I
- I
terminal I
end O
. O

In O
COL O
4 O
A O
5 O
intron B
41 I
a I
mutation I
changing I
the I
splice I
acceptor I
site I
from I
AG I
to I
AA I
was O
identified O
. O

In O
a O
control O
population O
of O
50 O
individuals O
tested O
by O
PCR O
- O
SSCP O
these O
mutations O
were O
never O
identified O
. O

Deletion B
of I
Glu I
137 I
by I
a I
trinucleotide I
deletion I
blocks O
intracellular O
transport O
. O

By O
sequencing O
all O
the O
coding O
exons O
and O
exon O
- O
intron O
boundaries O
of O
the O
gene O
, O
a B
trinucleotide I
deletion I
in I
exon I
VII I
that I
results I
in I
deletion I
of I
Glu I
137 I
was O
identified O
. O

Using O
DNA O
samples O
amplified O
with O
the O
polymerase O
chain O
reaction O
, O
hybridization O
analysis O
by O
oligonucleotide O
probes O
confirmed O
the O
presence O
of O
this O
mutation O
in O
all O
the O
affected O
family O
members O
, O
including O
both O
parents O
. O

These O
results O
suggest O
that O
the O
Glu B
137 I
deletion I
leads O
to O
the O
alpha O
2 O
- O
plasmin O
inhibitor O
deficiency O
by O
causing O
a O
block O
in O
its O
intracellular O
transport O
from O
the O
endoplasmic O
reticulum O
to O
the O
Golgi O
complex O
. O

One O
mutation O
was O
a O
G O
3295 O
T O
substitution O
with O
conversion O
of O
asparagine B
to I
tyrosine I
( I
D I
1099 I
Y I
) I
in O
ABCA O
1 O
. O

The O
single B
- I
base I
substitution I
at I
codon I
1099 I
resulted O
in O
the O
abolition O
of O
an O
Rsa O
I O
cleavage O
site O
. O

The O
proband O
and O
affected O
individuals O
having O
another O
mutation O
were O
heterozygotes O
for O
T O
5966 O
C O
with O
phenylalanine B
converted I
to I
serine I
( I
F I
2009 I
S I
) I
. O

In O
the O
kindred O
, O
family O
members O
heterozygous O
for O
the O
ABCA O
1 O
variant O
exhibited O
low O
levels O
of O
HDL O
cholesterol O
. O

Site O
- O
directed O
mutagenesis B
of I
active I
site I
glutamate I
- I
217 I
in O
mouse O
adenosine O
deaminase O
. O

Mouse O
adenosine O
deaminase O
( O
ADA O
) O
contains O
an O
active O
site O
glutamate O
residue O
at O
position O
- O
217 O
that O
is O
highly O
conserved O
in O
other O
adenosine O
and O
AMP O
deaminases O
. O

Glu B
217 I
was I
mutated I
to I
Asp I
, I
Gly I
, I
Gln I
, I
and I
Ser I
, O
and O
all O
mutants O
were O
successfully O
expressed O
and O
purified O
. O

RESULTS O
: O
Of O
the O
four O
mutations O
detected O
, O
two O
novel O
mutations O
were O
identified O
in O
the O
two O
patients O
, O
i O
. O
e O
. O
, O
F O
474 O
L O
, O
and O
an O
insertion B
of I
an I
adenine I
between I
nucleotide I
positions I
395 I
and I
396 I
. O

CONCLUSIONS O
: O
We O
established O
the O
molecular O
basis O
of O
butyrylcholinesterase O
deficiency O
in O
two O
Chinese O
patients O
. O

RESULTS O
: O
A O
single O
G B
- I
> I
T I
transversion I
was I
identified I
within I
the I
first I
coding I
exon I
of O
the O
Lim O
2 O
gene O
in O
the O
To O
3 O
mutant O
DNA O
. O

This O
DNA O
change O
results O
in O
the O
nonconservative B
substitution I
of I
a I
valine I
for I
the I
normally I
encoded I
glycine I
at I
amino I
acid I
15 I
of O
the O
MP O
19 O
polypeptide O
. O

Future O
transgenic O
experiments O
should O
provide O
proof O
or O
disproof O
of O
a O
causative O
relationship O
between O
the O
identified O
mutation O
and O
the O
cataractous O
phenotype O
. O

The O
F O
allele O
differed O
from O
the O
normal O
M O
1 O
( B
Val I
213 I
) I
alpha I
1 I
AT I
allele I
by I
a I
single I
nucleotide I
transversion I
of I
cytosine I
to I
thymidine I
, O
which O
results O
in O
the O
amino O
acid O
substitution O
Arg O
223 O
CGT O
- O
- O
- O
- O
Cys O
TGT O
. O

Deletion B
of I
the I
USF I
2 I
basic I
region I
or I
mutation I
of I
its I
helices I
abrogated O
its O
binding O
to O
c O
- O
Maf O
, O
but O
had O
no O
effect O
on O
homodimerization O
. O

Therefore O
, O
USF O
2 O
and O
c O
- O
Maf O
may O
interact O
to O
regulate O
gene O
expression O
. O

Nearly O
all O
studies O
have O
associated O
the O
presence O
( B
insertion I
, I
I I
) I
or I
absence I
( I
deletion I
, I
D I
) I
of I
a I
287 I
- I
bp I
Alu I
repeat I
element I
in I
intron I
16 I
with O
the O
levels O
of O
circulating O
enzyme O
or O
cardiovascular O
pathophysiologies O
. O

The O
diversity O
uncovered O
in O
DCP O
1 O
is O
comparable O
to O
that O
described O
for O
other O
regions O
in O
the O
human O
genome O
. O

Presenile O
dementia O
and O
cerebral O
haemorrhage O
linked O
to O
a O
mutation B
at I
codon I
692 I
of O
the O
beta O
- O
amyloid O
precursor O
protein O
gene O
. O

Several O
families O
with O
an O
early O
- O
onset O
form O
of O
familial O
Alzheimer O
' O
s O
disease O
have O
been O
found O
to O
harbour O
mutations B
at I
a I
specific I
codon I
( I
717 I
) I
of O
the O
gene O
for O
the O
beta O
- O
amyloid O
precursor O
protein O
( O
APP O
) O
on O
chromosome O
21 O
. O

The O
mutation O
results O
in O
the O
substitution B
of I
alanine I
into I
glycine I
at I
codon I
692 I
. O

Extracellular O
- O
regulated O
kinase O
3 O
( O
ERK O
3 O
, O
MAPK O
6 O
) O
is O
an O
atypical O
member O
of O
the O
ERKs O
, O
lacking B
the I
threonine I
and I
tyrosine I
residues I
in I
the I
activation I
loop I
, O
carrying O
a O
unique O
C O
- O
terminal O
extension O
and O
being O
mainly O
regulated O
by O
its O
own O
protein O
stability O
and O
/ O
or O
by O
autophosphorylation O
. O

Deletion B
of I
MK I
5 I
leads O
to O
strong O
reduction O
of O
ERK O
3 O
protein O
levels O
and O
embryonic O
lethality O
at O
about O
stage O
E O
11 O
, O
where O
ERK O
3 O
expression O
in O
wild O
- O
type O
mice O
is O
maximum O
, O
indicating O
a O
role O
of O
this O
signalling O
module O
in O
development O
. O

The O
sequence O
of O
the O
complete O
P O
5 O
' O
N O
- O
1 O
gene O
showed O
the O
presence O
of O
four O
different O
new O
mutations O
: O
a O
missense B
mutation I
AAT I
- I
AGT I
at I
codon I
190 I
( I
Asn I
- I
Ser I
) I
, I
one B
splicing I
mutation I
( I
IVS I
9 I
- I
1 I
g I
- I
c I
) I
and O
two B
frameshift I
mutations I
, I
Del I
G I
576 I
and I
Ins I
GG I
743 I
. O

An O
increase O
in O
serum O
ferritin O
levels O
was O
observed O
in O
the O
splenectomized O
patients O
, O
suggesting O
that O
the O
iron O
status O
of O
these O
subjects O
should O
be O
monitored O
and O
that O
they O
should O
be O
investigated O
for O
potential O
additional O
risk O
factors O
for O
iron O
accumulation O
. O

Five B
amino I
acid I
substitutions I
between I
these I
molecules I
were I
shown I
to I
be I
located I
on I
the I
beta I
- I
strand I
of I
alpha I
1 I
and I
alpha I
2 I
domains I
, O
suggesting O
that O
they O
might O
change O
the O
conformational O
allodeterminants O
on O
the O
alpha O
- O
helical O
region O
of O
Cw O
1 O
which O
were O
recognized O
by O
antibodies O
. O

Six B
of I
nine I
amino I
acid I
substitutions I
between I
these I
molecules I
were I
observed I
on I
alpha I
1 I
and I
alpha I
2 I
domains I
, O
whereas O
three O
other O
substitutions B
were I
located I
on I
the I
leader I
peptide I
, I
the I
alpha I
3 I
domain I
and I
the I
transmembrane I
. O

Two B
substitutions I
( I
residues I
73 I
and I
163 I
) I
of I
the I
alpha I
- I
helical I
region I
of I
the I
alpha I
1 I
and I
alpha I
2 I
domains I
and O
one O
( O
residue O
16 O
) O
of O
exposed O
loop O
may O
make O
new O
allodeterminants O
which O
are O
not O
recognized O
by O
anti O
- O
Cw O
2 O
sera O
as O
well O
as O
other O
alloantisera O
. O

Both O
gene O
products O
were O
expressed O
stably O
on O
the O
surface O
of O
these O
cells O
. O

The O
proband O
is O
a O
50 O
year O
- O
old O
woman O
born O
from O
a O
consanguineous O
marriage O
. O

The O
sequence O
of O
ATP O
- O
binding O
cassette O
transporter O
1 O
( O
ABC O
1 O
- O
1 O
) O
c O
DNA O
obtained O
by O
reverse O
transcription O
- O
PCR O
( O
RT O
- O
PCR O
) O
of O
total O
RNA O
isolated O
from O
cultured O
fibroblasts O
showed O
that O
the O
proband O
was O
homozygous O
for O
a O
C B
> I
T I
transition I
in I
exon I
13 I
, O
which B
caused I
a I
tryptophane I
for I
arginine I
substitution O
( O
R O
527 O
W O
) O
. O

We O
found O
that O
the O
locus B
D I
17 I
S I
829 I
was I
homozygously I
deleted I
in O
23 O
out O
of O
70 O
patients O
, O
and O
identified O
a O
novel O
gene O
, O
CTNS O
, O
which O
mapped O
to O
the O
deletion O
interval O
. O

CAL O
contains O
two O
predicted O
coiled O
- O
coil O
domains O
and O
one O
PSD O
- O
95 O
/ O
Discs O
- O
large O
/ O
ZO O
- O
1 O
homology O
( O
PDZ O
) O
domain O
. O

Mutation B
of I
the I
terminal I
valine I
residue I
resulted O
in O
markedly O
reduced O
association O
of O
the O
beta O
1 O
AR O
- O
CT O
with O
CAL O
. O

In O
cells O
, O
full O
- O
length O
beta O
1 O
AR O
robustly O
associates O
with O
CAL O
, O
and O
this O
interaction O
is O
abolished O
by O
mutation B
of I
the I
terminal I
valine I
to I
alanine I
of O
the O
receptor O
( O
V O
477 O
A O
) O
, O
as O
determined O
by O
co O
- O
immunoprecipitation O
experiments O
and O
immunofluorescence O
co O
- O
localization O
studies O
. O

Besides O
the O
common O
N O
370 O
S O
, O
L O
444 O
P O
, O
Rec O
Nci O
I O
, O
G O
202 O
R O
, O
IVS O
2 O
+ O
1 O
G O
> O
A O
, O
D O
409 O
H O
, O
F O
213 O
I O
mutations O
, O
the O
different O
molecular O
strategies O
, O
used O
for O
the O
mutation O
detection O
, O
identified O
the O
rare O
N O
107 O
L O
, O
R O
131 O
C O
, O
R O
170 O
C O
, O
R O
170 O
P O
, O
N O
188 O
S O
, O
S O
196 O
P O
, O
R O
285 O
C O
, O
R O
285 O
H O
, O
W O
312 O
C O
, O
D O
399 O
N O
, O
A O
446 O
P O
, O
IVS O
10 O
- O
1 O
G O
> O
A O
, O
Rec O
Delta O
55 O
, O
total B
gene I
deletion I
, O
as O
well O
as O
12 O
mutant O
alleles O
that O
were O
exclusively O
present O
in O
the O
Italian O
population O
until O
now O
: O
the O
previously O
reported O
R O
353 O
G O
, O
N O
370 O
S O
+ O
S O
488 O
P O
mosaicism O
, O
IVS O
8 O
( O
- O
11 O
del O
C O
) O
- O
14 O
T O
> O
A O
) O
, O
Rec O
I O
, O
Y O
418 O
C O
, O
and O
the O
seven O
novel O
alleles O
D O
127 O
X O
, O
P O
159 O
T O
, O
V O
214 O
X O
, O
T O
231 O
R O
, O
L O
354 O
X O
, O
H O
451 O
R O
, O
and O
G O
202 O
R O
+ O
M O
361 O
I O
. O

An O
A B
to I
G I
transition I
at I
position I
985 I
that O
causes O
a O
lysine B
- I
304 I
to I
glutamate I
substitution I
in O
the O
mature O
protein O
is O
the O
single O
prevalent O
mutation O
. O

In O
all O
three O
patients O
, O
an O
A B
to I
G I
transition I
was I
identified I
at I
position I
985 I
of I
the I
coding I
region I
. O

When O
c O
DNA O
or O
genomic O
DNA O
from O
fibroblasts O
of O
nine O
MCAD O
- O
deficient O
patients O
were O
tested O
with O
this O
method O
, O
the O
copies O
from O
all O
of O
them O
completely O
cleaved O
into O
two O
shorter O
fragments O
by O
Nco O
I O
, O
indicating O
their O
homozygosity O
for O
the O
A B
- I
- I
- I
- I
G I
- I
985 I
transition I
. O

Thus O
, O
this O
A B
- I
- I
- I
- I
G I
- I
985 I
transition I
is O
the O
single O
prevalent O
mutation O
causing O
MCAD O
deficiency O
, O
a O
highly O
unusual O
feature O
for O
any O
genetic O
disorder O
. O

The O
absence O
of O
restriction O
fragment O
length O
polymorphism O
by O
Southern O
blot O
analysis O
and O
the O
finding O
that O
all O
of O
the O
amplified O
DNA O
fragments O
possess O
the O
expected O
length O
suggest O
the O
absence O
of O
deletions O
, O
duplications O
, O
or O
re O
- O
arrangements O
in O
the O
other O
allele O
. O

A O
putative B
second I
mutation I
could I
be I
located I
farther I
than I
1427 I
basepairs I
upstream I
of I
the I
initiation I
codon I
, O
thus O
potentially O
affecting O
the O
normal O
expression O
of O
this O
gene O
or O
within O
intronic O
regions O
, O
generating O
an O
alternative O
aberrant O
splicing O
site O
. O

Site O
- O
directed O
mutagenesis O
has O
been O
used O
to O
construct O
an O
active O
, O
oxidation O
- O
resistant O
derivative O
containing O
a O
single B
methionine I
to I
valine I
substitution I
at I
the I
active I
centre I
. O

This O
demonstrates O
the O
potential O
of O
engineered O
modifications O
to O
protein O
molecules O
designed O
to O
improve O
their O
physiological O
function O
. O

By O
using O
the O
PCR O
to O
amplify O
the O
coding O
sequence O
of O
the O
ACTH O
receptor O
gene O
, O
we O
identified O
three O
mutations O
in O
two O
unrelated O
patients O
. O

One O
mutation O
present O
in O
homozygous O
form O
converted B
the I
negatively I
charged I
Asp I
107 I
, I
located I
in I
the I
third I
transmembrane I
domain I
, I
to I
an I
uncharged I
Asn I
residue I
. O

The O
second O
patient O
was O
a O
compound O
heterozygote O
: O
the O
paternal O
allele O
contained O
a O
one O
- O
nucleotide O
insertion O
leading O
to O
a O
stop O
codon O
within O
the O
third O
extracellular O
loop O
, O
and O
the O
maternal B
allele I
contained I
a I
point I
mutation I
converting I
Cys I
251 I
to I
Phe I
, O
also O
in O
the O
third O
extracellular O
loop O
. O

Mutation O
profiling O
of O
positional O
- O
candidate O
genes O
detected O
a O
heterozygous O
transversion O
( O
c O
. O
386 O
A O
- O
- O
> O
T O
) O
in O
exon O
3 O
of O
the O
gene O
for O
chromatin O
modifying O
protein O
- O
4 O
B O
( O
CHMP O
4 O
B O
) O
that O
was O
predicted O
to O
result O
in O
the O
nonconservative O
substitution O
of O
a O
valine B
residue I
for I
a I
phylogenetically I
conserved I
aspartic I
acid I
residue I
at I
codon I
129 I
( O
p O
. O
D O
129 O
V O
) O
. O

In O
addition O
, O
we O
have O
detected O
a O
heterozygous O
transition O
( O
c O
. O
481 O
G O
- O
- O
> O
A O
) O
in O
exon O
3 O
of O
CHMP O
4 O
B O
cosegregating O
with O
autosomal O
dominant O
posterior O
polar O
cataracts O
in O
a O
Japanese O
family O
that O
was O
predicted O
to O
result O
in O
the O
missense O
substitution O
of O
lysine B
for I
a I
conserved I
glutamic I
acid I
residue I
at I
codon I
161 I
( O
p O
. O
E O
161 O
K O
) O
. O

Furthermore O
, O
mice O
with O
specific O
deletion B
of I
Erb O
B O
4 O
in O
parvalbumin O
interneurons O
were O
more O
susceptible O
to O
pentylenetetrazole O
- O
and O
pilocarpine O
- O
induced O
models O
of O
epilepsy O
. O

Erb O
B O
4 O
may O
be O
a O
new O
target O
for O
anticonvulsant O
drugs O
in O
epilepsy O
. O

The O
cerebellar O
c O
DNA O
yielded O
a O
derived O
primary O
structure O
which O
differed O
from O
the O
liver O
E O
3 O
amino O
acid O
sequence O
by O
a O
single B
serine I
- I
to I
- I
cysteine I
substitution I
at I
position I
88 I
( I
position I
84 I
in I
the I
liver I
sequence I
) O
. O

The O
catalytic O
properties O
of O
the O
brain O
variant O
were O
indistinguishable O
from O
those O
of O
E O
3 O
, O
and O
so O
the O
functional O
importance O
of O
this O
variant O
is O
at O
present O
unknown O
. O

RESULTS O
: O
The O
1 O
st O
patient O
had O
a O
single O
missense O
mutation O
in O
his O
copy O
of O
the O
KAL O
1 O
gene O
, O
a B
T I
→ I
G I
transversion I
in I
codon I
134 I
that I
results I
in I
replacement I
of I
cysteine I
by I
gly I
cine I
. O

The O
2 O
nd O
affected O
subject O
had O
a O
single O
missense O
mutation O
in O
the O
KAL O
1 O
gene O
, O
a O
T B
→ I
C I
transition I
in I
codon I
163 I
that I
results I
in I
replacement I
of I
cysteine I
by I
arginine I
. O

The O
3 O
rd O
case O
was O
hemizygous O
for O
a O
nonsense B
mutation I
in I
codon I
424 I
of I
exon I
9 I
( I
c I
. I
CGA I
→ I
TGA I
) I
of O
the O
KAL O
1 O
gene O
. O

This O
mutation O
predicts O
a O
markedly O
truncated O
protein O
. O

Changes B
at I
P I
183 I
of O
emerin O
weaken O
its O
protein O
- O
protein O
interactions O
resulting O
in O
X O
- O
linked O
Emery O
- O
Dreifuss O
muscular O
dystrophy O
. O

Mutations O
spanning O
the O
emerin O
gene O
have O
been O
identified O
in O
patients O
with O
EDMD O
. O

These O
alterations O
predict O
the O
replacement B
of I
a I
proline I
residue I
at I
position I
183 I
with I
either I
a I
histidine I
or I
a I
threonine I
. O

In O
comparison O
with O
the O
usual O
EDMD O
phenotype O
, O
patients O
with O
P B
183 I
missense I
mutations I
have O
a O
Knockdown B
of I
IFT I
81 I
and O
rescue O
experiments O
with O
point O
mutants O
showed O
that O
tubulin O
binding O
by O
IFT O
81 O
was O
required O
for O
ciliogenesis O
in O
human O
cells O
. O

Protein O
kinase O
M O
- O
ζ O
( O
PKM O
- O
ζ O
) O
is O
a O
constitutively O
active O
form O
of O
atypical O
protein O
kinase O
C O
that O
is O
exclusively O
expressed O
in O
the O
brain O
and O
implicated O
in O
the O
maintenance O
of O
long O
- O
term O
memory O
. O

Here O
we O
use O
a O
genetic O
approach O
and O
target O
exon O
9 O
of O
the O
Prkcz O
gene O
to O
generate O
mice O
that O
lack B
both I
protein I
kinase I
C I
- I
ζ I
( I
PKC I
- I
ζ I
) I
and I
PKM I
- I
ζ I
( I
Prkcz I
( I
- I
/ I
- I
) I
mice I
) I
. O

Here O
we O
show O
that O
human O
- O
papillomavirus O
- O
associated O
tumours O
are O
dominated O
by O
helical B
domain I
mutations I
of O
the O
oncogene O
PIK O
3 O
CA O
, O
novel O
alterations O
involving O
loss B
of I
TRAF I
3 I
, O
and O
amplification O
of O
the O
cell O
cycle O
gene O
E O
2 O
F O
1 O
. O

Smoking O
- O
related O
HNSCCs O
demonstrate O
near O
universal O
loss O
- O
of O
- O
function O
TP O
53 O
mutations O
and O
CDKN O
2 O
A O
inactivation O
with O
frequent O
copy O
number O
alterations O
including O
amplification B
of I
3 I
q I
26 I
/ I
28 I
and I
11 I
q I
13 I
/ I
22 I
. O

SHANK O
3 O
and O
IGF O
1 O
restore O
synaptic O
deficits O
in O
neurons O
from O
22 B
q I
13 I
deletion I
syndrome O
patients O
. O

PMDS O
is O
caused O
by O
heterozygous B
deletions I
of I
chromosome I
22 I
q I
13 I
. I
3 I
. O

Among O
the O
genes O
in O
the O
deleted B
region I
is I
SHANK I
3 I
, O
which O
encodes O
a O
protein O
in O
the O
postsynaptic O
density O
( O
PSD O
) O
. O

Our O
findings O
provide O
direct O
evidence O
for O
a O
disruption O
in O
the O
ratio O
of O
cellular O
excitation O
and O
inhibition O
in O
PMDS O
neurons O
, O
and O
point O
to O
a O
molecular O
pathway O
that O
can O
be O
recruited O
to O
restore O
it O
. O

An O
estimated O
13 B
. I
7 I
somatic I
L I
1 I
insertions I
occurred O
per O
hippocampal O
neuron O
and O
carried O
the O
sequence O
hallmarks O
of O
target O
- O
primed O
reverse O
transcription O
. O

Notably O
, O
hippocampal B
neuron I
L I
1 I
insertions I
were O
specifically O
enriched O
in O
transcribed O
neuronal O
stem O
cell O
enhancers O
and O
hippocampus O
genes O
, O
increasing O
their O
probability O
of O
functional O
relevance O
. O

In O
addition O
, O
bias O
against O
intronic B
L I
1 I
insertions I
sense O
oriented O
relative O
to O
their O
host O
gene O
was O
observed O
, O
perhaps O
indicating O
moderate O
selection O
against O
this O
configuration O
in O
vivo O
. O

Squamous O
cell O
carcinomas O
have O
higher O
frequencies O
of O
somatic O
nucleotide B
substitutions I
occurring I
at I
cytosines I
preceded I
by I
thymines I
( I
Tp I
* I
C I
sites I
) I
than O
adenocarcinomas O
. O

These O
data O
demonstrate O
several O
recurrent O
genomic O
alterations O
in O
cervical O
carcinomas O
that O
suggest O
new O
strategies O
to O
combat O
this O
disease O
. O

Inefficient O
Brr O
2 O
repression O
is O
the O
only O
recognizable O
phenotype O
associated O
with O
certain O
retinitis O
pigmentosa O
- O
linked O
Prp O
8 O
mutations B
that I
map I
to I
its I
C I
- I
terminal I
tail I
. O

Clustered B
missense I
mutations I
were I
found I
at I
the I
amino I
- I
terminal I
portion I
of I
the I
delta I
subunit I
of O
guanine O
nucleotide O
exchange O
factor O
( O
GEF O
) O
e O
IF O
2 O
B O
. O

Despite O
a O
clear O
heritable O
component O
, O
the O
genetic O
aetiology O
leading O
to O
non O
- O
syndromic O
MVP O
has O
remained O
elusive O
. O

Morpholino B
knockdown I
of O
the O
zebrafish O
homologue O
dachsous O
1 O
b O
resulted O
in O
a O
cardiac O
atrioventricular O
canal O
defect O
that O
could O
be O
rescued O
by O
wild O
- O
type O
human O
DCHS O
1 O
, O
but O
not O
by O
DCHS O
1 O
messenger O
RNA O
with O
the O
familial O
mutation O
. O

Deletion B
of I
the I
class I
2 I
KNOTTED I
1 I
- I
LIKE I
HOMEOBOX I
( O
KNOX O
2 O
) O
transcription O
factors O
in O
the O
moss O
Physcomitrella O
patens O
results O
in O
the O
development O
of O
gametophyte O
bodies O
from O
diploid O
embryos O
without O
meiosis O
. O

Two O
tumours O
with O
wild O
- O
type O
RB O
1 O
had O
evidence O
of O
chromothripsis O
leading O
to O
overexpression O
of O
cyclin O
D O
1 O
( O
encoded O
by O
the O
CCND O
1 O
gene O
) O
, O
revealing O
an O
alternative O
mechanism O
of O
Rb O
1 O
deregulation O
. O

Thus O
, O
loss B
of I
the I
tumour I
suppressors I
TP I
53 I
and I
RB I
1 I
is O
obligatory O
in O
SCLC O
. O

Arrestins O
interact O
with O
G O
- O
protein O
- O
coupled O
receptors O
( O
GPCRs O
) O
to O
block O
interaction O
with O
G O
proteins O
and O
initiate O
G O
- O
protein O
- O
independent O
signalling O
. O

Structures O
of O
the O
inactive O
state O
of O
arrestin O
are O
available O
, O
but O
it O
is O
not O
known O
how O
C B
- I
tail I
displacement I
activates O
arrestin O
for O
receptor O
coupling O
. O

Here O
we O
present O
a O
3 O
. O
0 O
Å O
crystal O
structure O
of O
the O
bovine O
arrestin O
- O
1 O
splice O
variant O
p O
44 O
, O
in O
which O
the O
activation O
step O
is O
mimicked O
by O
C B
- I
tail I
truncation I
. O

The O
data O
indicate O
a O
mechanism O
for O
arrestin O
activation O
in O
which O
C B
- I
tail I
displacement I
releases O
critical O
central O
- O
crest O
loops O
from O
restricted O
to O
extended O
receptor O
- O
interacting O
conformations O
. O

Fin O
Major O
results O
in O
a O
proline B
- I
phenylalanine I
- I
glutamine I
peptide I
insertion I
within I
the I
uncharacterized I
Gle I
1 I
coiled I
- I
coil I
domain I
. O

Moreover O
, O
functional O
assays O
document O
a O
specific O
requirement O
for O
proper O
Gle O
1 O
oligomerization O
during O
m O
RNA O
export O
, O
but O
not O
for O
Gle O
1 O
' O
s O
roles O
in O
translation O
. O

Changes O
in O
gene O
dosage O
are O
a O
major O
driver O
of O
cancer O
, O
known O
to O
be O
caused O
by O
a O
finite O
, O
but O
increasingly O
well O
annotated O
, O
repertoire O
of O
mutational O
mechanisms O
. O

This O
can O
potentially O
generate O
correlated O
copy O
- O
number O
alterations O
across O
hundreds O
of O
linked O
genes O
, O
as O
exemplified O
by O
the O
2 O
% O
of O
childhood O
acute O
lymphoblastic O
leukaemia O
( O
ALL O
) O
with O
recurrent O
amplification B
of I
megabase I
regions I
of I
chromosome I
21 I
( O
i O
AMP O
21 O
) O
. O

Here O
we O
show O
that O
individuals O
born O
with O
the O
rare O
constitutional O
Robertsonian B
translocation I
between I
chromosomes I
15 I
and I
21 I
, O
rob O
( O
15 O
; O
21 O
) O
( O
q O
10 O
; O
q O
10 O
) O
c O
, O
have O
approximately O
2 O
, O
700 O
- O
fold O
increased O
risk O
of O
developing O
i O
AMP O
21 O
ALL O
compared O
to O
the O
general O
population O
. O

Here O
, O
we O
discover O
that O
loss B
of I
GTPBP I
2 I
, O
a O
novel O
binding O
partner O
of O
the O
ribosome O
recycling O
protein O
Pelota O
, O
in O
mice O
with O
a O
mutation O
in O
a O
t O
RNA O
gene O
that O
is O
specifically O
expressed O
in O
the O
central O
nervous O
system O
causes O
ribosome O
stalling O
and O
widespread O
neurodegeneration O
. O

Nonetheless O
, O
how O
micro O
RNAs O
regulate O
skeletal O
biology O
is O
underexplored O
. O

Conversely O
, O
mi B
R I
- I
34 I
a I
knockout I
and I
heterozygous I
mice O
exhibit O
elevated O
bone O
resorption O
and O
reduced O
bone O
mass O
. O

Tgif B
2 I
deletion I
reduces O
bone O
resorption O
and O
abolishes O
mi O
R O
- O
34 O
a O
regulation O
. O

Over O
70 O
% O
of O
diffuse O
intrinsic O
pediatric O
gliomas O
, O
an O
aggressive O
brainstem O
tumor O
, O
harbor O
heterozygous O
mutations O
that O
create O
a O
K O
27 O
M O
amino O
acid O
substitution O
( O
methionine B
replaces I
lysine I
27 I
) O
in O
the O
tail O
of O
histone O
H O
3 O
. O
3 O
. O

Cardiac O
function O
and O
mitochondrial O
morphology O
were O
rescued O
by O
Oma B
1 I
deletion I
, O
which O
prevented O
OPA O
1 O
cleavage O
. O

Thus O
, O
unprocessed O
OPA O
1 O
is O
sufficient O
to O
maintain O
heart O
function O
, O
OMA O
1 O
is O
a O
critical O
regulator O
of O
cardiomyocyte O
survival O
, O
and O
mitochondrial O
morphology O
and O
cardiac O
metabolism O
are O
intimately O
linked O
. O

The O
linear O
ubiquitin O
( O
Ub O
) O
chain O
assembly O
complex O
( O
LUBAC O
) O
is O
an O
E O
3 O
ligase O
that O
specifically O
assembles O
Met O
1 O
- O
linked O
( O
also O
known O
as O
linear O
) O
Ub O
chains O
that O
regulate O
nuclear O
factor O
κ O
B O
( O
NF O
- O
κ O
B O
) O
signaling O
. O

Mutation B
of I
Ub I
Glu I
16 I
inhibits O
OTULIN O
activity O
by O
reducing O
kcat O
240 O
- O
fold O
. O

Recent O
reports O
demonstrated O
a O
crucial O
role O
for O
interleukin O
- O
1 O
β O
( O
IL O
- O
1 O
β O
) O
in O
osteomyelitis O
, O
but O
deletion B
of I
the I
inflammasome I
components I
caspase I
- I
1 I
and I
NLRP I
3 I
failed O
to O
rescue O
Pstpip O
2 O
( O
cmo O
) O
mice O
from O
inflammatory O
bone O
disease O
. O

Thus O
, O
the O
upstream O
mechanisms O
controlling O
IL O
- O
1 O
β O
production O
in O
Pstpip O
2 O
( O
cmo O
) O
mice O
remain O
to O
be O
identified O
. O

We O
further O
demonstrate O
that O
combined B
deletion I
of I
caspases I
1 I
and I
8 I
was O
required O
for O
protection O
against O
IL O
- O
1 O
β O
- O
dependent O
inflammatory O
bone O
disease O
, O
whereas O
the O
deletion B
of I
either I
caspase I
alone I
or I
of I
elastase I
or I
neutrophil I
proteinase I
3 I
failed O
to O
prevent O
inflammatory O
disease O
. O

We O
identified O
a O
specific O
disruption O
of O
synaptic O
transmission O
at O
thalamocortical O
glutamatergic O
projections O
in O
the O
auditory O
cortex O
in O
murine O
models O
of O
schizophrenia O
- O
associated O
22 B
q I
11 I
deletion I
syndrome I
( O
22 O
q O
11 O
DS O
) O
. O

Interfering O
with O
mitochondrial O
fusion O
mechanisms O
in O
Agrp O
neurons O
by O
cell O
- O
selectively O
knocking B
down I
mitofusin I
1 I
( I
Mfn I
1 I
) I
or I
mitofusin I
2 I
( I
Mfn I
2 I
) I
resulted O
in O
altered O
mitochondria O
size O
and O
density O
in O
these O
cells O
. O

Agrp O
- O
specific O
Mfn B
1 I
or I
Mfn I
2 I
knockout I
mice O
gained O
less O
weight O
when O
fed O
a O
HFD O
due O
to O
decreased O
fat O
mass O
. O

Cancer O
stem O
cells O
( O
CSCs O
) O
have O
been O
reported O
in O
various O
cancers O
, O
including O
in O
skin O
squamous O
- O
cell O
carcinoma O
( O
SCC O
) O
. O

Conditional O
deletion B
of I
Sox I
2 I
in O
the O
mouse O
epidermis O
markedly O
decreases O
skin O
tumour O
formation O
after O
chemical O
- O
induced O
carcinogenesis O
. O

Conditional O
Sox B
2 I
deletion I
in O
pre O
- O
existing O
skin O
papilloma O
and O
SCC O
leads O
to O
tumour O
regression O
and O
decreases O
the O
ability O
of O
cancer O
cells O
to O
be O
propagated O
upon O
transplantation O
into O
immunodeficient O
mice O
, O
supporting O
the O
essential O
role O
of O
SOX O
2 O
in O
regulating O
CSC O
functions O
. O

Transcriptional O
profiling O
of O
SOX O
2 O
- O
GFP O
- O
expressing O
CSCs O
and O
of O
tumour O
epithelial O
cells O
upon O
Sox B
2 I
deletion I
uncovered O
a O
gene O
network O
regulated O
by O
SOX O
2 O
in O
primary O
tumour O
cells O
in O
vivo O
. O

Using O
genome O
sequencing O
, O
we O
characterized O
the O
somatic O
evolution O
of O
a O
genetically O
engineered O
mouse O
model O
( O
GEMM O
) O
of O
SCLC O
initiated O
by O
loss B
of I
Trp I
53 I
and I
Rb I
1 I
. O

Alterations O
targeting O
the O
tumor O
suppressor O
Pten O
occurred O
in O
the O
majority O
of O
murine O
SCLC O
studied O
, O
and O
engineered B
Pten I
deletion I
accelerated O
murine O
SCLC O
and O
abrogated B
loss I
of I
Chr I
19 I
in I
Trp I
53 I
; I
Rb I
1 I
; I
Pten I
compound I
mutant I
tumors I
. O

Both B
absence I
and I
overproduction I
of I
Toddler I
reduce O
the O
movement O
of O
mesendodermal O
cells O
during O
zebrafish O
gastrulation O
. O

Deletion B
of I
phenylalanine I
508 I
of O
the O
cystic O
fibrosis O
transmembrane O
conductance O
regulator O
( O
∆ O
F O
508 O
CFTR O
) O
is O
the O
major O
cause O
of O
cystic O
fibrosis O
, O
one O
of O
the O
most O
common O
inherited O
childhood O
diseases O
. O

The O
mutated O
CFTR O
anion O
channel O
is O
not O
fully O
glycosylated O
and O
shows O
minimal O
activity O
in O
bronchial O
epithelial O
cells O
of O
patients O
with O
cystic O
fibrosis O
. O

Our O
results O
demonstrate O
that O
global O
remodelling O
of O
∆ O
F O
508 O
CFTR O
interactions O
is O
crucial O
for O
rescue O
, O
and O
provide O
comprehensive O
insight O
into O
the O
molecular O
disease O
mechanisms O
of O
cystic O
fibrosis O
caused O
by O
deletion B
of I
F I
508 I
. O

Criteria O
for O
inference O
of O
chromothripsis B
in O
cancer O
genomes O
. O

Chromothripsis B
scars O
the O
genome O
when O
localized O
chromosome O
shattering O
and O
repair O
occurs O
in O
a O
one O
- O
off O
catastrophe O
. O

Outcomes O
of O
this O
process O
are O
detectable O
as O
massive B
DNA I
rearrangements I
affecting O
one O
or O
a O
few O
chromosomes O
. O

Although O
recent O
findings O
suggest O
a O
crucial O
role O
of O
chromothripsis B
in O
cancer O
development O
, O
the O
reproducible O
inference O
of O
this O
process O
remains O
challenging O
, O
requiring O
that O
cataclysmic B
one I
- I
off I
rearrangements I
be O
distinguished O
from O
localized O
lesions O
that O
occur O
progressively O
. O

We O
describe O
conceptual O
criteria O
for O
the O
inference O
of O
chromothripsis B
, O
based O
on O
ruling O
out O
the O
alternative O
hypothesis O
that O
stepwise O
rearrangements O
occurred O
. O

Robust O
means O
of O
inference O
may O
facilitate O
in O
- O
depth O
studies O
on O
the O
impact O
of O
, O
and O
the O
mechanisms O
underlying O
, O
chromothripsis B
. O

Data O
from O
rare O
male O
patients O
suggest O
symptom O
onset O
and O
severity O
can O
be O
influenced O
by O
the O
location B
of I
the I
mutation I
, I
with I
amino I
acids I
270 I
and I
273 I
marking O
the O
difference O
between O
neonatal O
encephalopathy O
and O
death O
, O
on O
the O
one O
hand O
, O
and O
survival O
with O
deficits O
on O
the O
other O
. O

We O
discovered O
that O
Me O
CP O
2 O
contains O
three O
AT O
- O
hook O
- O
like O
domains O
over O
a O
stretch O
of O
250 O
amino O
acids O
, O
like O
HMGA O
DNA O
- O
bending O
proteins O
; O
one B
conserved I
AT I
- I
hook I
is I
disrupted I
in O
Me O
CP O
2 O
- O
R O
270 O
X O
, O
lending O
further O
support O
to O
the O
notion O
that O
one O
of O
Me O
CP O
2 O
' O
s O
key O
functions O
is O
to O
alter O
chromatin O
structure O
. O

Recent O
studies O
suggest O
that O
upregulation O
of O
transforming O
growth O
factor O
( O
TGF O
) O
- O
β O
signalling O
triggered O
by O
PTEN B
loss I
will O
form O
a O
growth O
barrier O
as O
a O
defence O
mechanism O
to O
constrain O
prostate O
cancer O
progression O
, O
underscoring O
that O
TGF O
- O
β O
signalling O
might O
represent O
a O
pre O
- O
invasive O
checkpoint O
to O
prevent O
PTEN O
- O
mediated O
prostate O
tumorigenesis O
. O

Overexpression O
of O
COUP O
- O
TFII O
in O
the O
mouse O
prostate O
epithelium O
cooperates O
with O
PTEN B
deletion I
to O
augment O
malignant O
progression O
and O
produce O
an O
aggressive O
metastasis O
- O
prone O
tumour O
. O

The O
functional O
counteraction O
between O
COUP O
- O
TFII O
and O
SMAD O
4 O
is O
reinforced O
by O
genetically O
engineered O
mouse O
models O
in O
which O
conditional O
loss B
of I
SMAD I
4 I
diminishes O
the O
inhibitory O
effects O
elicited O
by O
COUP O
- O
TFII O
ablation O
. O

Missense B
mutations I
of I
some I
arginine I
residues I
at I
the I
surface I
of O
α O
- O
TTP O
cause O
severe O
vitamin O
E O
deficiency O
in O
humans O
, O
but O
the O
role O
of O
these O
residues O
is O
unclear O
. O

We O
specifically O
demonstrate O
that O
loss B
of I
CTCF I
at I
a I
domain I
boundary I
permits O
a O
constitutive O
enhancer O
to O
interact O
aberrantly O
with O
the O
receptor O
tyrosine O
kinase O
gene O
PDGFRA O
, O
a O
prominent O
glioma O
oncogene O
. O

Conversely O
, O
CRISPR O
- O
mediated O
disruption O
of O
the O
CTCF O
motif O
in O
IDH O
wild O
- O
type O
gliomaspheres O
upregulates O
PDGFRA O
and O
increases O
proliferation O
. O

AML B
with I
inv I
( I
3 I
) I
/ I
t I
( I
3 I
; I
3 I
) I
is O
associated O
with O
aberrant B
expression I
of I
the I
stem I
- I
cell I
regulator I
EVI I
1 I
. O

Applying O
functional O
genomics O
and O
genome O
- O
engineering O
, O
we O
demonstrate O
that O
both B
3 I
q I
rearrangements I
reposition I
a I
distal I
GATA I
2 I
enhancer I
to O
ectopically O
activate O
EVI O
1 O
and O
simultaneously O
confer O
GATA O
2 O
functional O
haploinsufficiency O
, O
previously O
identified O
as O
the O
cause O
of O
sporadic O
familial O
AML O
/ O
MDS O
and O
Mono O
Mac O
/ O
Emberger O
syndromes O
. O

Genomic B
excision I
of I
the I
ectopic I
enhancer I
restored O
EVI O
1 O
silencing O
and O
led O
to O
growth O
inhibition O
and O
differentiation O
of O
AML O
cells O
, O
which O
could O
be O
replicated O
by O
pharmacologic O
BET O
inhibition O
. O

In O
a O
small O
fraction O
of O
patients O
with O
schizophrenia O
or O
autism O
, O
alleles O
of O
copy B
- I
number I
variants I
( O
CNVs O
) O
in O
their O
genomes O
are O
probably O
the O
strongest O
factors O
contributing O
to O
the O
pathogenesis O
of O
the O
disease O
. O

Controls O
carrying O
the O
chromosome O
15 B
q I
11 I
. I
2 I
deletion I
between I
breakpoints I
1 I
and I
2 I
( O
15 B
q I
11 I
. I
2 I
( I
BP I
1 I
- I
BP I
2 I
) I
deletion I
) O
have O
a O
history O
of O
dyslexia O
and O
dyscalculia O
, O
even O
after O
adjusting O
for O
IQ O
in O
the O
analysis O
, O
and O
the O
CNV O
only O
confers O
modest O
effects O
on O
other O
cognitive O
traits O
. O

The O
15 B
q I
11 I
. I
2 I
( I
BP I
1 I
- I
BP I
2 I
) I
deletion I
affects O
brain O
structure O
in O
a O
pattern O
consistent O
with O
both O
that O
observed O
during O
first O
- O
episode O
psychosis O
in O
schizophrenia O
and O
that O
of O
structural O
correlates O
in O
dyslexia O
. O

We O
report O
compound O
heterozygous O
null B
mutations I
in I
IRF I
7 I
, O
which O
encodes O
the O
transcription O
factor O
interferon O
regulatory O
factor O
7 O
, O
in O
an O
otherwise O
healthy O
child O
who O
suffered O
life O
- O
threatening O
influenza O
during O
primary O
infection O
. O

Polq O
inhibition O
suppresses O
alternative O
NHEJ O
at O
dysfunctional O
telomeres O
, O
and O
hinders O
chromosomal O
translocations O
at O
non O
- O
telomeric O
loci O
. O

In O
addition O
, O
we O
found O
that O
loss B
of I
Polq I
in O
mice O
results O
in O
increased O
rates O
of O
homology O
- O
directed O
repair O
, O
evident O
by O
recombination O
of O
dysfunctional O
telomeres O
and O
accumulation O
of O
RAD O
51 O
at O
double O
- O
stranded O
breaks O
. O

Here O
, O
we O
report O
that O
checkpoint O
kinase O
2 O
( O
Chk O
2 O
or O
Chek O
2 O
) O
, O
is O
essential O
for O
culling O
mouse O
oocytes O
bearing O
unrepaired O
meiotic O
or O
induced O
DNA B
double I
- I
strand I
breaks I
( O
DSBs O
) O
. O

Surprisingly O
, O
our O
studies O
of O
a O
knock B
- I
in I
mutant I
mouse I
strain I
that I
expresses I
a I
stabilized I
and I
transcriptionally I
dead I
variant I
of I
the I
tumour I
- I
suppressor I
protein I
p I
53 I
( I
p I
53 I
( I
25 I
, I
26 I
, I
53 I
, I
54 I
) I
) I
, O
along O
with O
a O
wild O
- O
type O
allele O
of O
p O
53 O
( O
also O
known O
as O
Trp O
53 O
) O
, O
revealed O
late O
- O
gestational O
embryonic O
lethality O
associated O
with O
a O
host O
of O
phenotypes O
that O
are O
characteristic O
of O
CHARGE O
syndrome O
, O
including O
coloboma O
, O
inner O
and O
outer O
ear O
malformations O
, O
heart O
outflow O
tract O
defects O
and O
craniofacial O
defects O
. O

Furthermore O
, O
we O
found O
that O
CHD O
7 O
can O
bind O
to O
the O
p O
53 O
promoter O
, O
thereby O
negatively O
regulating O
p O
53 O
expression O
, O
and O
that O
CHD B
7 I
loss I
in O
mouse O
neural O
crest O
cells O
or O
samples O
from O
patients O
with O
CHARGE O
syndrome O
results O
in O
p O
53 O
activation O
. O

Strikingly O
, O
we O
found O
that O
p O
53 O
heterozygosity O
partially O
rescued O
the O
phenotypes O
in O
Chd O
7 O
- O
null O
mouse O
embryos O
, O
demonstrating O
that O
p O
53 O
contributes O
to O
the O
phenotypes O
that O
result O
from O
CHD B
7 I
loss I
. O

Nitrate O
is O
a O
primary O
nutrient O
for O
plant O
growth O
, O
but O
its O
levels O
in O
soil O
can O
fluctuate O
by O
several O
orders O
of O
magnitude O
. O

Using O
a O
cell O
- O
based O
fluorescence O
resonance O
energy O
transfer O
assay O
, O
we O
show O
that O
functional O
NRT O
1 O
. O
1 O
dimerizes O
in O
the O
cell O
membrane O
and O
that O
the O
phosphomimetic O
mutation B
of I
Thr I
101 I
converts O
the O
protein O
into O
a O
monophasic O
high O
- O
affinity O
transporter O
by O
structurally O
decoupling O
the O
dimer O
. O

Mutational B
inactivation I
of I
the I
Lxx I
LL I
binding I
pocket I
disrupts O
the O
oncogenic O
activities O
of O
both O
E O
6 O
proteins O
. O

Chromatin O
remodeling O
at O
DNA O
double B
- I
strand I
breaks I
. O

DNA O
double B
- I
strand I
breaks I
( O
DSBs O
) O
can O
arise O
from O
multiple O
sources O
, O
including O
exposure O
to O
ionizing O
radiation O
. O

Consequently O
, O
nucleosome O
packing O
and O
chromatin O
architecture O
surrounding O
the O
DSB B
may O
limit O
the O
ability O
of O
the O
DNA O
- O
damage O
response O
to O
access O
and O
repair O
the O
break O
. O

Here O
, O
we O
review O
early O
chromatin O
- O
based O
events O
that O
promote O
the O
formation O
of O
open O
, O
relaxed O
chromatin O
structures O
at O
DSBs O
and O
that O
allow O
the O
DNA O
- O
repair O
machinery O
to O
access O
the O
spatially O
confined O
region O
surrounding O
the O
DSB B
, O
thereby O
facilitating O
mammalian O
DSB B
repair O
. O

We O
also O
found O
that O
neurotoxicity O
was O
prevented O
by O
deletions B
of I
the I
octapeptide I
repeats I
within I
the I
flexible I
tail I
. O

These O
deletions O
did O
not O
appreciably O
compromise O
globular O
domain O
antibody O
binding O
, O
suggesting O
that O
the O
flexible O
tail O
is O
required O
to O
transmit O
toxic O
signals O
that O
originate O
from O
the O
globular O
domain O
and O
trigger O
oxidative O
stress O
and O
calpain O
activation O
. O

We O
find O
that O
a O
deficiency O
in O
the O
M O
2 O
pyruvate O
kinase O
isoform O
( O
PKM O
2 O
) O
reduces O
the O
levels O
of O
metabolic O
intermediates O
important O
for O
biosynthesis O
and O
impairs O
progenitor O
function O
without O
perturbing O
hematopoietic O
stem O
cells O
( O
HSCs O
) O
, O
whereas O
lactate B
dehydrogenase I
A I
( I
LDHA I
) I
deletion I
significantly O
inhibits O
the O
function O
of O
both O
HSCs O
and O
progenitors O
during O
hematopoiesis O
. O

In O
contrast O
, O
leukemia O
initiation O
by O
transforming O
alleles O
putatively O
affecting O
either O
HSCs O
or O
progenitors O
is O
inhibited O
in O
the O
absence B
of I
either I
PKM I
2 I
or I
LDHA I
, O
indicating O
that O
the O
cell O
- O
state O
- O
specific O
responses O
to O
metabolic O
manipulation O
in O
hematopoiesis O
do O
not O
apply O
to O
the O
setting O
of O
leukemia O
. O

